AKR1C2 and cancer: Among these, sulfotransferases (SULT1A1, SULT1A2, SULT1A3) and aldo-keto reductases (AKR1C1, AKR1C2, AKR1C3) were shown to contribute to disease progression and/or represent therapeutic targets in hormone-dependent forms of cancer [85, 86], including EOC [87].